University of Pittsburgh Clinical and Translational Science Institute

匹兹堡大学临床与转化科学研究所

• 批准号: 10216856
• 负责人: STEVEN E REIS
• 金额: $ 84.29万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10216856
• 关键词: 2019-nCoV; Academic Medical Centers; Affect; Antibodies; Antibody titer measurement; Biological Assay; Biological Markers; Blood specimen; COVID-19; COVID-19 pandemic; Caregivers; Clinical Research; Clinical Sciences; Communities; Development; Diagnosis; Disease; Economics; Emotional; Enzyme-Linked Immunosorbent Assay; Exposure to; Family; Family Caregiver; Future; General Population; Genetic Predisposition to Disease; Goals; Health; Health Services Accessibility; Herd Immunity; Housing; Humoral Immunities; Immune; Immunity; Immunoglobulin G; Immunoglobulin M; Individual; Infection; Institutes; Intramural Research Program; Knowledge; Life Cycle Stages; Measures; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; National Institute of Biomedical Imaging and Bioengineering; Outcome; Participant; Persons; Population; Prevalence; Proteins; Public Health; Rare Diseases; Reporting; Seroprevalences; Surveys; Symptoms; Therapeutic immunosuppression; Translational Research; United States; United States National Institutes of Health; Universities; Vaccines; Viral; Virus; high risk; insight; medical appointment; medical supply; mortality; novel; pandemic disease; research study; response; screening

ABSTRACT The pandemic caused by the SARS-CoV-2 virus continues to impact public health and the health of individuals, families, and communities. Those with a rare disease may be disproportionately affected because they may have a high risk of exposure to SARS-CoV-2 from their caregivers, housing situations, and need to attend in- person medical appointments. They may also be particularly vulnerable to complications from infection due to their underlying disease condition, immunosuppressive therapies, genetic susceptibility, and/or other factors. The scope of infection among those with rare diseases is unknown. The present proposal will investigate the sero-prevalence of immunity against SARS-CoV-2 among asymptomatic individuals with rare diseases. Specifically, this study will determine the prevalence of detectable antibodies to SARS-CoV-2 (Aim 1) and investigate the immune attributes associated with health outcomes across the life course (Aim 2) among asymptomatic individuals across the United States with one of >280 rare diseases. The anticipated results will provide crucial insights into the magnitude of the COVID-19 pandemic in the context of rare disease and will contribute to the identification of potential targets for a vaccine.

摘要 由SARS-CoV-2病毒引起的大流行继续影响公共卫生和个人健康， 家庭和社区。那些患有罕见疾病的人可能会受到不成比例的影响，因为他们可能 有高风险暴露于SARS-CoV-2从他们的照顾者，住房情况，并需要参加- 个人医疗预约他们也可能特别容易受到感染并发症， 它们的潜在疾病状况、免疫抑制疗法、遗传易感性和/或其他因素。 罕见疾病患者的感染范围尚不清楚。本提案将调查 在患有罕见疾病的无症状个体中对SARS-CoV-2的血清免疫率。 具体来说，这项研究将确定可检测到的SARS-CoV-2抗体的流行率（目的1）， 调查与整个生命过程中的健康结果相关的免疫属性（目标2）， 美国各地的无症状患者患有>280种罕见疾病之一。预期结果将 在罕见疾病的背景下，为COVID-19大流行的严重程度提供重要见解，并将 有助于确定疫苗的潜在靶点。